TP53 and cancer: The proportions of cancer cells containing 5-6 copies and >6 copies of MDR1 in the TP53 wild-type recurrent group were 36.0 ± 8.0% and 3.6 ± 0.7%, respectively, with no differences detected in the pre-treatment samples.